Miovský et al. suggest that the sustainability of harm reduction services in the region has been negatively affected by an under-investment in their institutionalisation.
Thomas D. Brothers et al. examine the encouraging metrics hospitals show in treating those with opioid dependencies and their positive impact after treatment has ended.
Niklas Karlsson et al. suggest delays in uptake and scale-up of harm reduction in Sweden could inform other countries' experiences toward implementing services.
Despite substantial, and welcomed, changes in the INCB's approach to human rights, reticences remain and point to structural conflicts between drug policy and human rights within the UN system.
The EU Civil Society Forum on Drugs assesses the health of civil society engagement at the European level, providing guiding principles and examples of good practice.
HRI underscores the importance of understanding the disruptions in provision caused by COVID-19 to inform donor and government action, including to mitigate gaps.
UNAIDS calls on countries to support community-led / based initiatives and adopt a new set of bold, yet achievable HIV targets, including in relation to repealing destructive criminalising laws.
Wolfe and Saucier argue that the success of future biotechnological treatments will rely on how the ethical considerations behind its applications will be addressed.
The HIV Policy Lab shines a light on policy barriers in access to high-quality HIV treatment and prevention, a key driver of new transmissions and deaths.
